1. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.
- Author
-
Kunz LI, van't Wout EF, van Schadewijk A, Postma DS, Kerstjens HA, Sterk PJ, and Hiemstra PS
- Subjects
- Adipokines blood, Adipokines genetics, Administration, Inhalation, Aged, Anti-Inflammatory Agents administration & dosage, Biomarkers metabolism, Bronchodilator Agents administration & dosage, Cells, Cultured, Chitinase-3-Like Protein 1, Dose-Response Relationship, Drug, Down-Regulation, Drug Administration Schedule, Female, Fluticasone-Salmeterol Drug Combination administration & dosage, Glucocorticoids administration & dosage, Humans, Inflammation Mediators metabolism, Inflammation Mediators pharmacology, Lectins blood, Lectins genetics, Macrophages immunology, Macrophages metabolism, Male, Middle Aged, Netherlands, Phenotype, Pulmonary Disease, Chronic Obstructive blood, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive genetics, Pulmonary Disease, Chronic Obstructive immunology, Sputum metabolism, Time Factors, Treatment Outcome, Adipokines metabolism, Anti-Inflammatory Agents pharmacology, Dexamethasone pharmacology, Glucocorticoids pharmacology, Lectins metabolism, Macrophages drug effects, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
Background: Macrophages constitute a heterogeneous cell population with pro- (MΦ1) and anti-inflammatory (MΦ2) cells. The soluble chitinase-like-protein YKL-40 is expressed in macrophages and various other cell types, and has been linked to a variety of inflammatory diseases, including COPD. Dexamethasone strongly reduces YKL-40 expression in peripheral blood mononuclear cells (PBMC) in vitro. We hypothesized that: a) YKL-40 is differentially expressed by MΦ1 and MΦ2, b) is decreased by corticosteroids and c) that long-term treatment with inhaled corticosteroids (ICS) affects YKL-40 levels in serum and sputum of COPD patients., Methods: Monocytes of healthy subjects were cultured in vitro for 7 days with either GM-CSF or M-CSF (for MΦ1 and MΦ2, respectively) and stimulated for 24 h with LPS, TNFα, or oncostatin M (OSM). MΦ1 and MΦ2 differentiation was assessed by measuring secretion of IL-12p40 and IL-10, respectively. YKL-40 expression in macrophages was measured by quantitative RT-PCR (qPCR) and ELISA; serum and sputum YKL-40 levels were analyzed by ELISA., Results: Pro-inflammatory MΦ1 cells secreted significantly more YKL-40 than MΦ2, which was independent of stimulation with LPS, TNFα or OSM (p < 0.001) and confirmed by qPCR. Dexamethasone dose-dependently and significantly inhibited YKL-40 protein and mRNA levels in MΦ1. Serum YKL-40 levels of COPD patients were significantly higher than sputum YKL-40 levels but were not significantly changed by ICS treatment., Conclusions: YKL-40 secretion from MΦ1 cells is higher than from MΦ2 cells and is unaffected by further stimulation with pro-inflammatory agents. Furthermore, YKL-40 release from cultured monocyte-derived macrophages is inhibited by dexamethasone especially in MΦ1, but ICS treatment did not change YKL-40 serum and sputum levels in COPD. These results indicate that YKL-40 expression could be used as a marker for MΦ1 macrophages in vitro, but not for monitoring the effect of ICS in COPD., Trial Registration: ClinicalTrials.gov, registration number: NCT00158847.
- Published
- 2015
- Full Text
- View/download PDF